Biotech Business - July 2, 2021
Xbrane Biopharma raises 380 million SEK
Xbrane has carried out a directed share issue of SEK 380 millions at a subscription price of SEK 135 per share. The subscription price was determined through an accelerated book-building procedure. A number of Swedish and international institutional investors, including Lancelot Asset Management, Serendipity Group, Swedbank Robur Fonder and TIN Fonder have subscribed for shares […]
Biotech Business - July 1, 2021
Immunicum receives Advanced Therapy Medicinal Product classification
The company has received Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency (EMA) for the company’s lead cancer relapse vaccine candidate, DCP-001. DCP-001 is derived from Immunicum’s human DCOne cell line and is currently being evaluated as a cancer relapse vaccine for the prevention of tumor recurrence in two ongoing clinical studies […]
Biotech Business - June 30, 2021
BioArctic’s lecanemab granted Breakthrough Therapy designation
BioArctic’s partner Eisai has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for lecanemab (BAN2401). BAN2401 is an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer’s disease. Based on a Phase 2b trial The FDA’s Breakthrough Therapy designation for lecanemab is based on the recently published […]
Agreement - May 26, 2021
Zelluna Immunotherapy enters license agreement
The company has announced two exclusive license agreements with The University of Texas MD Anderson Cancer Center related to MAGE-A4 and VGLL1 targeting allogeneic “off-the-shelf” TCR-NK cell therapies for the treatment of various solid cancers. Under the agreements Zelluna will have exclusive rights from MD Anderson to use characterized TCRs targeting MAGE-A4 and VGLL1 for […]
Biotech Business - May 25, 2021
Elicera enters a new development phase
Elicera Therapeutics has announced that the subscription period for the company’s new share issue prior to the planned listing on Nasdaq First North Growth Market began May 24 and runs until June 8. The new share issue consists of a directed issue of a maximum of 6,500,000 Units, each consisting of one (1) new share […]
Biotech Business - May 25, 2021
Lytix Biopharma prepares for listing on Euronext Growth Oslo
The board of directors of Lytix Biopharma has decided to apply for a listing of the company on Euronext Growth, simultaneously carrying out a capital increase. Lytix Biopharma has decided to initiate the process to secure funding of the company’s development program, including phase II clinical trials in the US for the lead candidate LTX-315. […]
